Ligand bias at the μ-opioid receptor

Biochemical Society Transactions

Volumn 41, Issue 1, 2013, Pages 218-224

  Kelly, Eamonn ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

opioid receptor; Arrestin; Biased agonism; Efficacy; G protein; GPCR

Indexed keywords

ARRESTIN 3; ENDOMORPHIN 2; G PROTEIN COUPLED RECEPTOR; MU OPIATE RECEPTOR; PHOSPHOLIPASE C; RETINA S ANTIGEN; UNCLASSIFIED DRUG;

CONCENTRATION RESPONSE; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; HUMAN; INTERNALIZATION; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION;

CELL LINE; HUMANS; LIGANDS; PHOSPHORYLATION; RECEPTORS, OPIOID, MU;

EID: 84873193960     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20120331     Document Type: Conference Paper

References (49)

1. Rang, H. P. (2006) The receptor concept: pharmacology's big idea. Br. J. Pharmacol. 147, S9-S16 (Pubitemid 43077257)
2. Swaminath, G., Xiang, Y., Lee, T. W., Steenhuis, J., Parnot, C. and Kobilka, B. K. (2004) Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J. Biol. Chem. 279, 686-691 (Pubitemid 38044873)
3. 2-adrenergic receptor. Nat. Chem. Biol. 7, 692-700
4. Bokoch, M. P., Zou, Y., Rasmussen, S. G., Liu, C. W., Nygaard, R., Rosenbaum, D. M., Fung, J. J., Choi, H. J., Thian, F. S., Kobilka, T. S. et al. (2010) Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463, 108-112
5. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M. et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1-13 (Pubitemid 46025713)
6. Kenakin, T. (2011) Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 336, 296-302
7. Whalen, E. J., Rajagopal, S. and Lefkowitz, R. J. (2011) Therapeutic potential of β-arrestin-and G protein-biased agonists. Trends Mol. Med. 17, 126-139
8. Gesty-Palmer, D., Flannery, P., Yuan, L., Corsino, L., Spurney, R., Lefkowitz, R. J. and Luttrell, L. M. (2009) A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci. Transl. Med. 1, 1ra1
9. Zimmerman, B., Beautrait, A., Aguila, B., Charles, R., Escher, E., Claing, A., Bouvier, M. and Laporte, S. A. (2012) Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci. Signaling 5, ra33
10. Walters, R. W., Shukla, A. K., Kovacs, J. J., Violin, J. D., DeWire, S. M., Lam, C. M., Chen, J. R., Muehlbauer, M. J., Whalen, E. J. and Lefkowitz, R. J. (2009) β-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J. Clin. Invest. 119, 1312-1321
11. Lohse, M. J., Nuber, S. and Hoffmann, C. (2012) Fluorescence/ bioluminescence resonance energy transfer techniques to study G-proteincoupled receptor activation and signaling. Pharmacol. Rev. 64, 299-336
12. Reversi, A., Rimoldi, V., Marrocco, T., Cassoni, P., Bussolati, G., Parenti, M. and Chini, B. (2005) The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism. J. Biol. Chem. 280, 16311-16318 (Pubitemid 40616759)
13. Groer, C. E., Schmid, C. L., Jaeger, A. M. and Bohn, L. M. (2011) Agonist-directed interactions with specific β-arrestins determine μ-opioid receptor trafficking, ubiquitination, and dephosphorylation. J. Biol. Chem. 286, 31731-31741
14. Furchgott, R. F. (1966) The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv. Drug Res. 3, 21-55
15. Black, J. W. and Leff, P. (1983) Operational models of pharmacological agonism. Proc. R. Soc. London, Ser. B 220, 141-162 (Pubitemid 14217337)
16. Ehlert, F. J. (2008) On the analysis of ligand-directed signaling at G protein-coupled receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 377, 549-577
17. Christopoulos, A. and El-Fakahany, E. E. (1999) Qualitative and quantitative assessment of relative agonist efficacy. Biochem. Pharmacol. 58, 735-748 (Pubitemid 29329522)
18. McPherson, J., Rivero, G., Baptist, M., Llorente, J., Al-Sabah, S., Krasel, C., Dewey, W. L., Bailey, C. P., Rosethorne, E. M., Charlton, S. J. et al. (2010) μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol. Pharmacol. 78, 756-766
19. Rajagopal, S., Ahn, S., Rominger, D. H., Gowen-MacDonald, W., Lam, C. M., Dewire, S. M., Violin, J. D. and Lefkowitz, R. J. (2011) Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 80, 367-377
20. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A. and Novick, S. (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3, 193-203
21. Bassoni, D. L., Raab, W. J., Achacoso, P. L., Loh, C. Y. and Wehrman, T. S. (2012) Measurements of β-arrestin recruitment to activated seven transmembrane receptors using enzyme complementation. Methods Mol. Biol. 897, 181-203
22. Rivero, G., Llorente, J., McPherson, J., Cooke, A., Mundell, S. J., McArdle, C. A., Rosethorne, E. M., Charlton, S. J., Krasel, C., Bailey, C. P. et al. (2012) Endomorphin-2: a biased agonist at the μ-opioid receptor. Mol. Pharmacol. 82, 178-188
23. Keith, D. E., Anton, B., Murray, S. R., Zaki, P. A., Chu, P. C., Lissin, D. V., Monteillet-Agius, G., Stewart, P. L., Evans, C. J. and von Zastrow, M. (1998) μ-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol. Pharmacol. 53, 377-384 (Pubitemid 28162857)
24. Whistler, J. L., Chuang, H. H., Chu, P., Jan, L. Y. and von Zastrow, M. (1999) Functional dissociation of μ-opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23, 737-746 (Pubitemid 29411563)
25. Johnson, E. E., Christie, M. J. and Connor, M. (2005) The role of opioid receptor phosphorylation and trafficking in adaptations to persistent opioid treatment. Neurosignals 14, 290-302 (Pubitemid 43877701)
26. Kelly, E., Bailey, C. P. and Henderson, G. (2008) Agonist-selective mechanisms of GPCR desensitization. Br. J. Pharmacol. 153, S379-S388 (Pubitemid 351340999)
27. Kelly, E. (2011) The subtleties of μ-opioid receptor phosphorylation. Br. J. Pharmacol. 164, 294-297
28. El Kouhen, R., Burd, A. L., Erickson-Herbrandson, L. J., Chang, C. Y., Law, P. Y. and Loh, H. H. (2001) Phosphorylation of Ser363, Thr370, and Ser375 residues within the carboxyl tail differentially regulates mu-opioid receptor internalization. J. Biol. Chem. 276, 12774-12780
29. Schulz, S., Mayer, D., Pfeiffer, M., Stumm, R., Koch, T. and Höllt, V. (2004) Morphine induces terminal μ-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J. 23, 3282-3289 (Pubitemid 39209152)
30. Lau, E. K., Trester-Zedlitz, M., Trinidad, J. C., Kotowski, S. J., Krutchinsky, A. N., Burlingame, A. L. and von Zastrow, M. (2011) Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection. Sci Signal. 4, ra52
31. Moulédous, L., Froment, C., Dauvillier, S., Burlet-Schiltz, O., Zajac, J. M. and Mollereau, C. (2012) GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors. J. Biol. Chem. 287, 12736-12749
32. Doll, C., Pöll, F., Peuker, K., Loktev, A., Glück, L. and Schulz, S. (2012) Deciphering μ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells. Br. J. Pharmacol. 167, 1259-1270
33. Feng, B., Li, Z. and Wang, J. B. (2011) Protein kinase C-mediated phosphorylation of the μ-opioid receptor and its effects on receptor signaling. Mol. Pharmacol. 79, 768-775
34. Chen, Y. J., Oldfield, S., Butcher, A. J., Tobin, A. B., Saxena, K., Gurevich, V. V., Benovic, J. L., Henderson, G. and Kelly, E. (2012) Identification of phosphorylation sites in the COOH-terminal tail of the μ-opioid receptor. J. Neurochem. 124, 189-199
35. Audet, M. and Bouvier, M. (2012) Restructuring G-protein-coupled receptor activation. Cell 151, 14-23
36. Granier, S. and Kobilka, B. (2012) A new era of GPCR structural and chemical biology. Nat. Chem. Biol. 8, 670-673
37. Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K. and Granier, S. (2012) Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 485, 321-326
38. Corbett, A. D., Henderson, G., McKnight, A. T. and Paterson, S. J. (2006) 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br. J. Pharmacol. 147, S153-S162 (Pubitemid 43077273)
39. Raehal, K. M., Schmid, C. L., Groer, C. E. and Bohn, L. M. (2011) Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol. Rev. 63, 1001-1019
40. Groer, C. E., Tidgewell, K., Moyer, R. A., Harding, W. W., Rothman, R. B., Prisinzano, T. E. and Bohn, L. M. (2007) An opioid agonist that does not induce μ-opioid receptor-arrestin interactions or receptor internalization. Mol. Pharmacol. 71, 549-557 (Pubitemid 46147920)
41. Xu, H., Partilla, J. S., Wang, X., Rutherford, J. M., Tidgewell, K., Prisinzano, T. E., Bohn, L. M. and Rothman, R. B. (2007) A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) μ-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse 61, 166-175 (Pubitemid 46106813)
42. Wilson, A. M., Soignier, R. D., Zadina, J. E., Kastin, A. J., Nores, W. L., Olson, R. D. and Olson, G. A. (2000) Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides 21, 1871-1874 (Pubitemid 32058862)
43. Varamini, P., Mansfeld, F. M., Blanchfield, J. T., Wyse, B. D., Smith, M. T. and Toth, I. (2012) Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation. PLoS ONE 7, e41909
44. Zheng, H., Loh, H. H. and Law, P. Y. (2008) β-Arrestin-dependent μ-opioid receptor-activated extracellular signal-regulated kinases (ERKs) translocate to nucleus in contrast to G protein-dependent ERK activation. Mol. Pharmacol. 73, 178-190 (Pubitemid 350294209)
45. Bohn, L., Lefkowitz, R., Gainetdinov, R., Peppel, K., Caron, M. and Lin, F. (1999) Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286, 2495-2498
46. Raehal, K. M., Walker, J. K. and Bohn, L. M. (2005) Morphine side effects in β-arrestin 2 knockout mice. J. Pharmacol. Exp. Ther. 314, 1195-1201 (Pubitemid 41205984)
47. Bohn, L. M., Dykstra, L. A., Lefkowitz, R. J., Caron, M. G. and Barak, L. S. (2004) Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol. Pharmacol. 66, 106-112 (Pubitemid 38822092)
48. Dang, V. C., Chieng, B., Azriel, Y. and Christie, M. J. (2011) Cellular morphine tolerance produced by β-arrestin-2-dependent impairment of μ-opioid receptor resensitization. J. Neurosci. 31, 7122-7130
49. Quillinan, N., Lau, E. K., Virk, M., von Zastrow, M. and Williams, J. T. (2011) Recovery from μ-opioid receptor desensitization after chronic treatment with morphine and methadone. J. Neurosci. 31, 4434-4443